Skip to main content

Advances in Immune Targeted Therapies

Monday, October 24, 2011 — Concurrent Symposia Session I

2:00 p.m. – 4:00 p.m.

Room E1/E2


  • Liliana Guedez, NCI
  • Shaden Kamhawi, NIAID


Immunology-based technologies have significantly contributed to the development of therapies that modulate the immune system. It is timely to discuss transfer of genetically modified T cells, vaccines, genetically engineered antibodies, and interleukins as some of the promising fronts in the war against many diseases. This symposium topic is of broad interest to NIH intramural investigators who have been leaders in the development and translational research of targeted immune therapeutics. As the results from clinical trials are provided, new and unexpected information is revealed; some mechanistic differences between preclinical models and humans are reported. This symposium will serve as a scientific platform to exchange cutting-edge clinical information on issues related to the immunotherapies, describe challenges encountered in the clinic, and discuss experimental approaches on how to improve the clinical translation of therapies that modulate the immune system.

Recent Developments in T-Cell Adoptive Immunotherapy for Cancer Treatment
Nicholas Restifo, NCI

Therapeutic Cancer Vaccines Combined with Standard Therapies in the Treatment of Human Carcinoma
Ravi A. Madan, NCI

Bench-to-Bedside Development of Anti-CD22 Immunotoxins for Childhood Acute Lymphoblastic Leukemia
Alan Wayne, NCI

Clinical Translation of Daclizumab for the Treatment of Multiple Sclerosis
Bibiana Bielekova, NINDS

Modulation of Myeloid-Derived Dendritic Cell Maturity: Unmasking a Novel Role for the Tumor Suppressor p15Ink4b in Immunity *FARE Award Winner
Joanna Fares, NCI

back to top